Single and Repeat Dose First Time in Human Study for an Intranasal H1/H3 Dual Antagonist in Healthy Male Subjects
Status:
Completed
Trial end date:
2008-05-26
Target enrollment:
Participant gender:
Summary
This is a double-blind, placebo-controlled, randomized single dose escalation study and a
double-blind, placebo-controlled, randomised parallel group 14-days once daily repeat dose
study to investigate safety, tolerability and pharmacokinetics of an intranasal H1/H3 dual
antagonist compound in healthy male subjects.